Legal & General Group’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-126
| Closed | -$5.68K | – | 3429 |
|
|
2024
Q1 | $5.68K | Sell |
126
-62
| -33% | -$2.8K | ﹤0.01% | 3285 |
|
|
2023
Q4 | $8.91K | Sell |
188
-648
| -78% | -$30.7K | ﹤0.01% | 3257 |
|
|
2023
Q3 | $33.9K | Sell |
836
-317
| -27% | -$12.8K | ﹤0.01% | 2908 |
|
|
2023
Q2 | $123K | Buy |
1,153
+535
| +87% | +$57K | ﹤0.01% | 2813 |
|
|
2023
Q1 | $184K | Buy |
618
+13
| +2% | +$3.88K | ﹤0.01% | 2617 |
|
|
2022
Q4 | $208K | Buy |
605
+42
| +7% | +$14.4K | ﹤0.01% | 2593 |
|
|
2022
Q3 | $107K | Buy |
563
+19
| +3% | +$3.61K | ﹤0.01% | 2798 |
|
|
2022
Q2 | $114K | Buy |
544
+19
| +4% | +$3.98K | ﹤0.01% | 2819 |
|
|
2022
Q1 | $176K | Buy |
525
+5
| +1% | +$1.68K | ﹤0.01% | 2711 |
|
|
2021
Q4 | $169K | Hold |
520
| – | – | ﹤0.01% | 2777 |
|
|
2021
Q3 | $252K | Buy |
520
+248
| +91% | +$120K | ﹤0.01% | 2613 |
|
|
2021
Q2 | $127K | Buy |
272
+12
| +5% | +$5.6K | ﹤0.01% | 2664 |
|
|
2021
Q1 | $179K | Sell |
260
-4
| -2% | -$2.75K | ﹤0.01% | 2476 |
|
|
2020
Q4 | $195K | Buy |
264
+149
| +130% | +$110K | ﹤0.01% | 2428 |
|
|
2020
Q3 | $80K | Sell |
115
-21
| -15% | -$14.6K | ﹤0.01% | 2548 |
|
|
2020
Q2 | $116K | Buy |
136
+70
| +106% | +$59.7K | ﹤0.01% | 2488 |
|
|
2020
Q1 | $24K | Sell |
66
-11
| -14% | -$4K | ﹤0.01% | 2847 |
|
|
2019
Q4 | $18K | Buy |
77
+14
| +22% | +$3.27K | ﹤0.01% | 3209 |
|
|
2019
Q3 | $7K | Hold |
63
| – | – | ﹤0.01% | 3302 |
|
|
2019
Q2 | $11K | Buy |
+63
| New | +$11K | ﹤0.01% | 3341 |
|